PT KALBE FARMA TBK. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,455 IDR | +0.34% |
|
-1.69% | -9.63% |
| Apr. 01 | PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 20 | Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy | MT |
| Sales 2024 * | 32,263B 2B | Sales 2025 * | 35,129B 2.18B | Capitalization | 67,302B 4.17B |
|---|---|---|---|---|---|
| Net income 2024 * | 3,439B 213M | Net income 2025 * | 3,572B 221M | EV / Sales 2024 * | 1.98 x |
| Net cash position 2024 * | 3,567B 221M | Net cash position 2025 * | 5,545B 344M | EV / Sales 2025 * | 1.76 x |
| P/E ratio 2024 * |
19.8
x | P/E ratio 2025 * |
18.9
x | Employees | 13,108 |
| Yield 2024 * |
2.16% | Yield 2025 * |
2.33% | Free-Float | 40.45% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.34% | ||
| 1 week | -1.69% | ||
| Current month | -1.36% | ||
| 1 month | +1.75% | ||
| 3 months | -7.91% | ||
| 6 months | -20.27% | ||
| Current year | -9.63% |
1 week
1 440.00
1 525.00
1 month
1 415.001 535.00
Current year
1 405.001 620.00
1 year
1 405.002 200.00
3 years
1 240.002 360.00
5 years
830.002 360.00
10 years
830.002 360.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vidjongtius
CEO | Chief Executive Officer | 59 | 96-12-31 |
| Director of Finance/CFO | - | 17-01-31 | |
| Chairman | 61 | 97-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Santoso Oen
BRD | Director/Board Member | 59 | 99-12-31 |
| Director/Board Member | 51 | 07-12-31 | |
| Chairman | 61 | 97-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.30% | 9 M€ | -3.31% | - | |
| 1.91% | 93 M€ | -7.90% | ||
| 1.89% | 2 M€ | -14.14% | ||
| 1.54% | 15 M€ | +6.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 1,455 | +0.34% | 24,631,000 |
End-of-day quote INDONESIA S.E., April 16, 2024
More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,455
IDR
Average target price
1,777
IDR
Spread / Average Target
+22.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.63% | 4.14B | |
| +28.79% | 673B | |
| +24.81% | 551B | |
| -7.64% | 348B | |
| +15.00% | 317B | |
| +5.99% | 288B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 195B | |
| -11.71% | 145B |
- Stock Market
- Equities
- KLBF Stock
